1. Home
  2. ARVN vs GAU Comparison

ARVN vs GAU Comparison

Compare ARVN & GAU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$8.04

Market Cap

658.2M

Sector

Health Care

ML Signal

HOLD

Logo Galiano Gold Inc.

GAU

Galiano Gold Inc.

HOLD

Current Price

$1.86

Market Cap

606.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARVN
GAU
Founded
2015
1999
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
658.2M
606.0M
IPO Year
2018
2006

Fundamental Metrics

Financial Performance
Metric
ARVN
GAU
Price
$8.04
$1.86
Analyst Decision
Buy
Buy
Analyst Count
19
2
Target Price
$15.05
$4.08
AVG Volume (30 Days)
680.3K
3.7M
Earning Date
05-04-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
58.84
N/A
EPS
N/A
N/A
Revenue
$262,600,000.00
N/A
Revenue This Year
N/A
$82.77
Revenue Next Year
N/A
$29.09
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.06
$1.22
52 Week High
$14.22
$3.62

Technical Indicators

Market Signals
Indicator
ARVN
GAU
Relative Strength Index (RSI) 46.65 36.46
Support Level $7.35 N/A
Resistance Level $10.18 $2.75
Average True Range (ATR) 0.41 0.12
MACD 0.17 -0.02
Stochastic Oscillator 70.20 18.55

Price Performance

Historical Comparison
ARVN
GAU

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

About GAU Galiano Gold Inc.

Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.

Share on Social Networks: